KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Revenue (2016 - 2025)

Historic Revenue for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $3.9 billion.

  • Regeneron Pharmaceuticals' Revenue rose 250.98% to $3.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $14.3 billion, marking a year-over-year increase of 99.21%. This contributed to the annual value of $14.3 billion for FY2025, which is 99.21% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Revenue stood at $3.9 billion for Q4 2025, which was up 250.98% from $3.8 billion recorded in Q3 2025.
  • Over the past 5 years, Regeneron Pharmaceuticals' Revenue peaked at $5.1 billion during Q2 2021, and registered a low of $50.0 million during Q1 2022.
  • Moreover, its 5-year median value for Revenue was $3.4 billion (2023), whereas its average is $3.2 billion.
  • Its Revenue has fluctuated over the past 5 years, first crashed by 9802.27% in 2022, then soared by 622420.0% in 2023.
  • Over the past 5 years, Regeneron Pharmaceuticals' Revenue (Quarter) stood at $5.0 billion in 2021, then crashed by 97.98% to $100.0 million in 2022, then surged by 3334.3% to $3.4 billion in 2023, then increased by 10.33% to $3.8 billion in 2024, then increased by 2.51% to $3.9 billion in 2025.
  • Its Revenue was $3.9 billion in Q4 2025, compared to $3.8 billion in Q3 2025 and $3.7 billion in Q2 2025.